Bio Blast reports plans to price initial public offering of its stock

Aegis Capital will assist in selling company's ordinary stock in deal

By Devika Patel

Knoxville, Tenn., Feb. 7 - Bio Blast Pharma Ltd. will conduct an initial public offering of its ordinary stock with a 45-day greenshoe, according to a Form F-1 filed Friday with the Securities and Exchange Commission.

Aegis Capital Corp. is the bookrunning manager.

Proceeds will be used for pre-clinical and clinical programs, personnel-related costs, preclinical research, working capital and other general corporate purposes.

The biopharmaceutical company is based in Tel Aviv, Israel. The company intends to list its common stock on the Nasdaq stock exchange.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.